PTAB Nixes Biosimilar Co.'s Bid For AbbVie Humira Review
The Patent Trial and Appeal Board has declined to institute an inter partes review of the asserted claims of a patent related to AbbVie's autoimmune disease drug Humira, which had sales...To view the full article, register now.
Already a subscriber? Click here to view full article